Drug intelligence / Profile preview

HNC1798

Development stage: Preclinical
Lead developer: Guangzhou Henovcom Bioscience
Modality: Small Molecules

Overview

HNC1798 is an investigational small molecule being developed by Guangzhou Henovcom Bioscience for the treatment of Parkinson's disease. While the company's pipeline includes other candidates for Parkinson's disease with defined targets, such as the MAO-B inhibitor HNC364, the specific biological target and mechanism of action for HNC1798 have not been publicly disclosed. The drug is currently in the early stages of development as part of Henovcom's portfolio of small molecule therapeutics for neurological and inflammatory conditions.

Beyond the preview

Go deeper on HNC1798.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HNC1798.

Explore the full profile